HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study.

AbstractOBJECTIVE:
We conducted a 12-week, randomized, double-blind, controlled clinical trial to evaluate the effectiveness and tolerability of high eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) omega-3 fatty acids and inositol as monotherapy and in combination in children with bipolar spectrum disorders.
METHOD:
Participants were children 5-12 years of age meeting DSM-IV diagnostic criteria for bipolar spectrum disorders (bipolar I or II disorder or bipolar disorder not otherwise specified [NOS]) and displaying mixed, manic, or hypomanic symptoms. Subjects with severe illness were excluded. Subjects were randomized to 1 of 3 treatment arms: inositol plus placebo, omega-3 fatty acids plus placebo, and the combined active treatment of omega-3 fatty acids plus inositol. Data were collected from February 2012 to November 2013.
RESULTS:
Twenty-four subjects were exposed to treatment (≥ 1 week of study completed) (inositol [n = 7], omega-3 fatty acids [n = 7], and omega-3 fatty acids plus inositol [n =10]). Fifty-four percent of the subjects completed the study. Subjects randomized to the omega-3 fatty acids plus inositol arm had the largest score decrease comparing improvement from baseline to end point with respect to the Young Mania Rating Scale (P < .05). Similar results were found for the Children's Depression Rating Scale (P < .05) and the Brief Psychiatric Rating Scale (P <.05).
CONCLUSION:
Results of this pilot randomized, double-blind, controlled trial suggest that the combined treatment of omega-3 fatty acids plus inositol reduced symptoms of mania and depression in prepubertal children with mild to moderate bipolar spectrum disorders. Results should be interpreted in light of limitations, which include exclusion of severely ill subjects, 54% completion rate, and small sample size.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier: NCT01396486.
AuthorsJanet Wozniak, Stephen V Faraone, James Chan, Laura Tarko, Mariely Hernandez, Jacqueline Davis, K Yvonne Woodworth, Joseph Biederman
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 76 Issue 11 Pg. 1548-55 (Nov 2015) ISSN: 1555-2101 [Electronic] United States
PMID26646031 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© Copyright 2015 Physicians Postgraduate Press, Inc.
Chemical References
  • Docosahexaenoic Acids
  • Inositol
  • Eicosapentaenoic Acid
Topics
  • Bipolar Disorder (drug therapy)
  • Child
  • Child, Preschool
  • Docosahexaenoic Acids (administration & dosage, pharmacology)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Eicosapentaenoic Acid (administration & dosage, pharmacology)
  • Female
  • Humans
  • Inositol (administration & dosage, pharmacology)
  • Male
  • Pilot Projects
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: